Private macular hole vitrectomy surgery London 2026

What is a macular hole?

A full-thickness macular hole (FTMH) is a localised, round, full-thickness defect of all neurosensory retinal layers at the centre of the macula (the fovea). It typically affects adults aged 55–75 years, women slightly more than men, and is caused by abnormal traction of the vitreous body on the fovea during age-related posterior vitreous detachment (PVD). When the vitreous is firmly adherent to the foveal centre and detaches asymmetrically, the resulting tangential and antero-posterior traction pulls a small disc of foveal tissue away, producing the characteristic round hole on optical coherence tomography (OCT).

The widely-used International Vitreomacular Traction Study (IVTS) classification (Duker et al., Ophthalmology 2013) defines the OCT stages: stage 1 — foveal pseudocyst with focal vitreo-foveal traction (impending hole); stage 2 — small full-thickness hole < 250 microns minimum linear diameter (MLD) with persistent vitreofoveal adhesion; stage 3 — medium full-thickness hole 250–400 microns MLD; stage 4 — large full-thickness hole > 400 microns MLD with complete posterior vitreous detachment. The MLD measured at the narrowest point of the hole on OCT and the basal hole diameter are the strongest pre-operative predictors of anatomical closure and visual outcome. Holes under 250 microns close in 95–100 per cent of cases; holes over 650 microns require advanced techniques (inverted ILM flap, free ILM flap) and have closure rates of 70–90 per cent.

Patients typically present with central distortion (metamorphopsia — straight lines appear wavy or kinked), a central blind spot on the Amsler grid, and a drop in best corrected visual acuity (BCVA) usually to 6/18–6/60 depending on the size and chronicity of the hole. The fellow eye has a 10–15 per cent risk of developing a macular hole over 5 years if the vitreous is still attached; this risk falls to under 1 per cent once a posterior vitreous detachment has completed.

UK 2026 macular hole surgery pricing, in detail

The following pricing reflects a CQC-registered UK vitreoretinal sample audited against published 2024 to 2026 self-pay tariffs from the major London VR centres. All-inclusive means consultation, imaging, biometry, theatre, anaesthetist, vitreoretinal consumables (cutter, light pipe, dye, gas), and the full 1-day, 2-week, 6-week and 3-month review pathway with OCT.

Itemised pricing should split consultation, imaging, theatre, anaesthetist, surgeon, and the structured follow-up pathway. The companion private vitrectomy price guide covers the broader vitreoretinal cost framework; for the related macular procedure, see the private epiretinal membrane peel surgery London guide.

What should be included in a private macular hole surgery package in the UK in 2026?

A defensible UK 2026 private macular hole package is built around high-resolution macular OCT, modern small-gauge vitrectomy, ILM peel with intra-operative dye, and an OCT-confirmed closure review pathway. Be wary of fees that look low until you add the "extras".

• Consultant vitreoretinal assessment — slit-lamp, dilated indirect ophthalmoscopy, scleral indentation of the peripheral retina to exclude retinal breaks before surgery.
• Macular OCT (Spectralis or Cirrus) — foveal radial scans, MLD measurement, basal hole diameter, ellipsoid zone integrity, external limiting membrane assessment, posterior vitreous status.
• Fundus imaging — ultra-widefield colour photography (Optos / Clarus), red-free, autofluorescence; B-scan ultrasound if no view.
• Axial length biometry (IOLMaster, Argos or Lenstar) — required for phacovitrectomy IOL power and to identify high myopia (axial length > 26 mm) which has implications for outcome.
• Day-case 25G or 27G valved-trocar PPV under sub-Tenon's or topical anaesthetic with optional intravenous sedation.
• Posterior vitreous detachment induction — if not already complete, with triamcinolone visualisation.
• ILM peel — dye-assisted (brilliant blue G as first choice; ICG with caution at low concentration and brief contact time); 2–3 disc diameter peel centred on the fovea using 25/27G ILM forceps.
• Gas tamponade — 20 per cent sulphur hexafluoride (SF6, lasts 2–3 weeks) for small/medium holes; 14 per cent perfluoropropane (C3F8, lasts 6–8 weeks) for large or chronic holes.
• Structured follow-up pathway — 1-day pressure and bubble check, 2-week OCT closure confirmation, 6-week BCVA and OCT review, 3-month final visual outcome.
• Posturing guidance and equipment — written posturing protocol; some surgeons supply face-down posturing equipment hire for the first week.

What does the evidence say about macular hole vitrectomy?

The clinical evidence base for macular hole surgery is one of the strongest in vitreoretinal practice, with three foundational papers underpinning modern UK 2026 practice.

• Kelly & Wendel (Arch Ophthalmol 1991) — the original demonstration that pars plana vitrectomy can anatomically close a full-thickness macular hole. Closure 58 per cent without ILM peel.
• Brooks (Ophthalmology 2000) — ILM peel raises closure rate to 92–95 per cent for small/medium holes; this is now standard of care.
• Michalewska et al. (Ophthalmology 2010) — the inverted ILM flap technique for large holes (> 400 microns) raises closure from 50–60 per cent to 90–98 per cent; visual recovery is also improved.
• Duker et al. (IVTS classification, Ophthalmology 2013) — OCT-based classification (stage 1 to 4 by MLD) is the dominant international framework.
• Manchester Large Macular Hole Study — UK-led series showing closure rates of 80–90 per cent in holes > 650 microns using inverted ILM flap.
• MIVI-TRUST programme (Stalmans et al.) and NICE TA297 — ocriplasmin (Jetrea) for vitreomacular traction and small holes (< 400 microns) is licensed but its UK uptake has been low because of cost-effectiveness limits and only modest closure rates (around 25–40 per cent).
• BEAVRS UK Vitreoretinal Society audit data — infection (post-op endophthalmitis) < 0.05 per cent, retinal detachment 1–3 per cent, IOP spike > 25 mmHg 6–15 per cent, RPE atrophy after ILM peel uncommon.
• Cochrane review on macular hole surgery — ILM peel reduces re-operation rate; no clear evidence that strict prolonged face-down posturing is necessary for small/medium holes when SF6 is used with adequate gas fill.
• Lois et al. FILMS trial (Ophthalmology 2011) — randomised trial confirming ILM peel benefit on anatomical and functional outcomes.
• RCOphth vitreoretinal commissioning — defines NHS pathways and quality indicators including 24-hour same-day-discharge pathways.

Standard PPV + ILM peel vs ILM flap vs autologous transplant: which is right for my hole?

The technique is dictated by the OCT minimum linear diameter, the duration the hole has been open, and whether this is a primary or re-do operation.

• Standard PPV + ILM peel + SF6 (workhorse, Brooks 2000) — for primary full-thickness macular holes with MLD up to ~400 microns. 25G or 27G PPV, posterior vitreous detachment induction with triamcinolone visualisation, ILM peel 2–3 disc diameters around the fovea using brilliant blue G or ICG dye, 20 per cent SF6 gas fill, face-down posturing 3–5 days. Closure 90–95 per cent. The most efficient and lowest-risk option.
• Inverted ILM flap (Michalewska 2010) — for large holes > 400 microns or holes open for > 6 months. ILM is peeled around the hole but a flap of ILM is left attached at the foveal edge and inverted across the hole to act as a glial scaffold. Closure 90–98 per cent; visual outcomes are better than standard PPV in this size range.
• Free ILM flap / autologous ILM transplant — reserved for re-do operations where the ILM has already been peeled at the previous surgery. A free piece of ILM is harvested from elsewhere on the macula or peripapillary region and transplanted into the hole.
• Autologous neurosensory retinal transplant — for the very largest holes (typically > 1000 microns) and chronic recalcitrant holes; a free retinal patch from the periphery is transplanted into the hole.
• Amniotic membrane plug — emerging option for refractory holes with no residual ILM and previous failed surgeries.
• Subretinal fluid hydrodissection / macular hydrodissection — useful in selected stiff chronic holes to mobilise the foveal edges.
• C3F8 gas instead of SF6 — longer-acting tamponade (6–8 weeks vs 2–3 weeks) for large, chronic or re-do holes; longer flight ban and longer posturing.
• Ocriplasmin (Jetrea, intravitreal pharmacologic vitreolysis) — small holes < 400 microns with persistent vitreomacular traction; closure 25–40 per cent in the MIVI-TRUST programme; mostly superseded by surgical vitrectomy in 2026 UK practice.

Who is a good candidate for macular hole vitrectomy?

Candidacy is determined by the OCT findings, the symptoms, the duration of the hole and the medical fitness for day-case vitreoretinal surgery.

• Full-thickness macular hole, IVTS stage 2 (MLD < 250 microns) — textbook candidate for prompt PPV + ILM peel + SF6; closure 95–100 per cent.
• Full-thickness macular hole, IVTS stage 3 (MLD 250–400 microns) — PPV + ILM peel + SF6; closure 90–95 per cent.
• Full-thickness macular hole, IVTS stage 4 (MLD > 400 microns) — PPV with inverted ILM flap + C3F8; closure 80–95 per cent.
• Chronic macular hole (open > 6 months) — vitrectomy still indicated but with attenuated visual recovery expectation; ILM flap recommended.
• Traumatic macular hole — observation first (40–50 per cent close spontaneously over 3–6 months); vitrectomy if persistent or symptomatic at 3 months.
• Symptomatic lamellar macular hole with epiretinal traction — PPV + ERM/ILM peel for visual or metamorphopsia decline; not all lamellar holes need surgery.
• Myopic macular hole (high myopia, axial length > 26 mm) — vitrectomy with ILM flap; higher rate of myopic retinoschisis and recurrence.
• Stage 1 (vitreomacular traction with foveal pseudocyst) — not yet a hole; observation, ocriplasmin or vitrectomy if symptoms warrant.
• Relative contraindications — very poor pre-op BCVA from co-existent dry AMD or other macular pathology; severe medical comorbidity unfit for day-case surgery; inability to comply with face-down posturing or upright posture for SF6/C3F8 retention.

NHS vs private macular hole vitrectomy in the UK 2026

The NHS commissions macular hole vitrectomy via the NHS England specialised vitreoretinal pathway and equivalent pathways in Scotland, Wales and Northern Ireland. NHS waits in 2026 are realistically 4–12 weeks from referral to surgery depending on the trust; this is much shorter than many NHS subspecialty pathways because macular hole is recognised as time-sensitive (visual recovery is best when surgery is performed within 6 months of symptom onset). NHS care is excellent and the only practical limitations are timing and choice of consultant.

Private macular hole vitrectomy in the UK in 2026 typically offers same-week consultant vitreoretinal assessment, 1–3 week surgery booking, choice of consultant, continuity of post-op care with the same surgeon, photographic and OCT documentation at every visit, and an established revision pathway. The medical standard of care is the same; the difference is wait time, choice of consultant and predictability of scheduling around work and travel commitments.

Does private medical insurance cover macular hole vitrectomy?

In 2026 most UK private medical insurers (Bupa, AXA Health, Aviva, Vitality, WPA) fund macular hole vitrectomy when documented by OCT and meeting policy criteria.

• OCT documentation required — macular OCT confirming a full-thickness defect of all neurosensory retinal layers (IVTS stage 2, 3 or 4), with the MLD documented at the narrowest part of the hole, accompanied by a clinical letter referencing the IVTS classification.
• CCSD / OPCS-4 codes — commonly used: C79.4 (pars plana vitrectomy NEC), C79.5 (vitrectomy with internal tamponade), C82.1 (peeling of internal limiting membrane of retina). The clinical letter should reference the relevant codes.
• Pre-authorisation — always obtain in writing before surgery; verbal authorisation is not enough. Most insurers require the consultant letter, the OCT scans and the BCVA documentation.
• Bupa, AXA Health, Aviva, Vitality, WPA — all routinely fund primary macular hole vitrectomy in 2026 when OCT-confirmed; re-do surgery is also covered with appropriate clinical justification.
• Phacovitrectomy — the combined cataract and vitrectomy operation is generally covered when the cataract is visually significant; some insurers code as two distinct procedures.
• Excess and shortfall — check the policy excess and any shortfall against the consultant's fee schedule; some insurers cap surgeon fees below typical London consultant VR rates.

Risks and side-effects of macular hole vitrectomy

Macular hole vitrectomy is a safe operation in trained hands with serious complications uncommon, but every patient should understand the realistic risk profile.

• Cataract progression — near-universal in phakic eyes over 55 within 12 months of vitrectomy. Most surgeons recommend combined phacovitrectomy in phakic eyes to address this prospectively.
• Failure to close (anatomic non-closure) — 5–10 per cent for standard PPV + ILM peel in stage 2–3 holes; 15–30 per cent for large stage 4 holes if a standard technique is used (lower with ILM flap). Re-do surgery is offered.
• Late re-opening — 2–5 per cent over 5 years, more in eyes with persistent cystoid macular oedema or epiretinal membrane.
• Retinal detachment — 1–3 per cent (BEAVRS UK audit), from peripheral retinal breaks at trocar entry sites or during PVD induction. Detected on routine post-op review; managed by additional vitrectomy +/- buckle.
• Endophthalmitis — serious post-op infection, < 0.05 per cent (BEAVRS UK audit data) with valved-trocar small-gauge PPV. Emergency vitrectomy and intravitreal antibiotics if it occurs.
• IOP spike — transient post-op pressure rise > 25 mmHg in 6–15 per cent (more with C3F8 than SF6); usually controlled with topical and oral pressure-lowering medication; rarely needs gas release.
• Dye toxicity (ICG specifically) — rare RPE atrophy at the peeled area; modern practice uses low-concentration ICG (0.05 per cent) with brief contact time, or brilliant blue G as a safer alternative.
• Inner retinal layer dimpling (DONFL) — dissociated optic nerve fibre layer changes after ILM peel; almost always asymptomatic and visible only on OCT.
• Visual field defects — small temporal or peripheral field defects in 5–15 per cent (Spaide; light pipe trauma; usually asymptomatic).
• Persistent metamorphopsia — even after anatomic closure, residual distortion in 20–40 per cent that improves slowly over 6–18 months.
• Suprachoroidal haemorrhage — rare (< 0.1 per cent), more in elderly hypertensive patients.
• Gas-related complications — pupil block from large gas fill (manageable with pupil dilation and posturing), no air travel until the gas bubble has fully absorbed (3 weeks for SF6, 6–8 weeks for C3F8).
• Pain — mild postoperative ache for 24–48 hours, easily controlled with paracetamol.
• Visual asymmetry — in unilateral cases, gas-filled eye sees only light/shadow for 1–3 weeks until the gas absorbs.

What to expect after macular hole vitrectomy

Most patients are home within 2–4 hours, comfortable within 24 hours, and posturing for the first week. Visual recovery is gradual over 3–6 months with continuing improvement up to 12 months.

• Day 0–1 — eye is patched after surgery, removed at the 1-day pressure check; mild dull ache controlled with paracetamol; vision in the operated eye is only light/shadow because of the gas bubble.
• Day 1–7 — face-down posturing protocol begins for SF6 (3–5 days typical; some surgeons omit for stage 2 holes); the bubble shrinks visibly through this period and the patient begins to see the upper edge of a horizon line within the bubble.
• Week 1–2 — gas bubble approximately half its original size for SF6; bedrest can give way to normal upright posture and gentle activity; 1-day, 1-week and 2-week pressure checks; OCT confirmation of closure at 2 weeks.
• Week 2–4 — gas bubble continues to absorb; vision improves dramatically as the bubble shrinks below the visual axis; light driving and non-strenuous work possible by week 3 in unilateral cases.
• Week 4–6 — bubble absorbed (SF6); BCVA review with comparison OCT showing ellipsoid zone integrity; metamorphopsia begins to improve; cataract may now be visually significant.
• Month 3 — final OCT and BCVA review; foveal anatomy assessed for closure pattern (V-type, U-type, W-type); residual metamorphopsia documented; cataract surgery planned if not already combined.
• Month 6–12 — continuing visual and metamorphopsia improvement as the photoreceptor outer segments and ellipsoid zone gradually recover; final BCVA gain typically 2–3 Snellen lines in 70–80 per cent of eyes.
• Air travel — absolutely no flying until the gas bubble has fully absorbed: 3 weeks for SF6 (20 per cent), 6–8 weeks for C3F8 (14 per cent). The cabin pressure drop causes catastrophic gas expansion and irreversible optic nerve damage.
• Driving — most patients drive at 3–6 weeks (SF6) once the bubble is below the visual axis and they meet the DVLA standard (Snellen 6/12 with both eyes open, 120-degree field).
• Annual surveillance — macular OCT and BCVA from year 2 onwards to detect rare late re-opening; fellow eye assessment for vitreomacular traction or symptomatic stage 1.

How to choose a UK macular hole surgery clinic in 2026

Macular hole surgery is a subspecialty vitreoretinal operation. The right consultant has done hundreds of these and works in a unit with proper VR theatre infrastructure.

• GMC specialist registered consultant ophthalmologist with documented vitreoretinal fellowship (Moorfields, Liverpool, Manchester, Bristol or international equivalent).
• Annual macular hole volume — ask: at least 50–100 PPV / ILM peels per year for primary cases, ≥ 20 per year for re-do work.
• CQC-registered theatre with proper VR setup (Constellation, EVA NEXUS, Stellaris Elite or equivalent) and a CQC rating of Good or Outstanding.
• Audit data — the surgeon should be willing to share their personal closure, re-operation, retinal detachment and endophthalmitis rates.
• Same-week assessment pathway — macular hole closure is more likely the sooner the operation is done; a unit with 2–4 week surgery booking is preferable to one with multi-month waits.
• OCT-documented case selection — a defensible discussion of IVTS stage, MLD, technique choice (standard vs ILM flap) and tamponade choice (SF6 vs C3F8).
• Posturing pragmatism — updated practice often does not require strict prolonged face-down posturing for small stage 2 holes; surgeons who still insist on 7-day strict posturing for every case may be behind current evidence.
• Written, itemised quote with explicit revision policy.
• Insurance fluency — experienced practice manager who handles Bupa, AXA, Aviva, Vitality, WPA pre-authorisation routinely.
• 24-hour out-of-hours access for the first 2 weeks; macular hole vitrectomy is a low-complication operation but rare endophthalmitis and retinal detachment are time-critical.

Frequently asked questions

How much does private macular hole vitrectomy cost in London in 2026?

UK 2026 self-pay macular hole vitrectomy in London costs £6,500–£9,500 per eye, all-inclusive. The fee covers a same-week consultant vitreoretinal assessment, dilated fundoscopy, high-resolution macular OCT, axial length biometry, 25G or 27G day-case pars plana vitrectomy under sub-Tenon's or topical local anaesthetic with optional sedation, ILM peel typically assisted with brilliant blue G or indocyanine green dye, 20 per cent SF6 or 14 per cent C3F8 gas tamponade, and the structured 1-day, 2-week, 6-week and 3-month review pathway with OCT confirmation of closure. Combined phacovitrectomy (with simultaneous cataract surgery) is typically £8,500–£11,500.

What is the success rate of macular hole surgery?

Anatomic closure on OCT is 95–100 per cent for small stage 2 holes (MLD < 250 microns), 90–95 per cent for medium stage 3 holes (250–400 microns), and 80–95 per cent for large stage 4 holes (> 400 microns) when an inverted ILM flap technique is used. Functional success — defined as a 2-line or greater Snellen BCVA gain at 6 months — occurs in 70–80 per cent of eyes overall; metamorphopsia continues to improve up to 12 months. Visual recovery is best when surgery is done within 6 months of symptom onset.

How long does macular hole surgery take and is it painful?

Macular hole vitrectomy takes 30–50 minutes per eye as a day-case under sub-Tenon's or topical local anaesthetic, with optional intravenous sedation if you prefer. You are awake but the eye is fully numb. There is no pain during surgery, just a sensation of pressure and the surgeon's light. Postoperatively there is a mild dull ache for 24–48 hours, easily controlled with paracetamol. Vision in the operated eye is reduced to light / shadow only for the first 1–3 weeks because of the gas bubble.

Do I really have to lie face-down for a week?

Modern practice is more pragmatic than the strict 7–10 day face-down protocols of the 1990s. For small/medium stage 2–3 holes filled with 20 per cent SF6, many surgeons recommend 3–5 days of face-down posturing during waking hours, with relaxed posturing at night. For large stage 4 holes or chronic holes filled with C3F8, 5–10 days of stricter posturing is more common. The Cochrane review and the PIMS trial suggest that prolonged strict posturing is not essential when an adequate gas fill is achieved — ask your surgeon what they recommend for your specific hole size and tamponade.

Will the NHS pay for my macular hole vitrectomy?

Yes. Macular hole vitrectomy is commissioned via the NHS England specialised vitreoretinal pathway and equivalent pathways in Scotland, Wales and Northern Ireland. Realistic NHS waits in 2026 are 4–12 weeks from referral to surgery, depending on the trust and the urgency triage on the OCT-documented stage. NHS care is excellent and the only practical limitations are timing and choice of consultant. Macular hole is recognised as time-sensitive (best visual recovery within 6 months of symptom onset) so NHS pathways prioritise these patients above many other cases.

Will my private medical insurance cover macular hole vitrectomy?

In 2026 Bupa, AXA Health, Aviva, Vitality and WPA generally cover macular hole vitrectomy when the diagnosis is OCT-confirmed (full-thickness defect of all neurosensory layers, IVTS stage 2, 3 or 4) and the clinical letter documents the indication, MLD, BCVA and the impact on quality of life. The relevant OPCS-4 codes (C79.4 vitrectomy NEC, C79.5 vitrectomy with internal tamponade, C82.1 ILM peel) should be referenced. Re-do surgery is generally covered with appropriate clinical justification. Always pre-authorise in writing.

What is the difference between SF6 and C3F8 gas?

SF6 (20 per cent sulphur hexafluoride) lasts 2–3 weeks in the eye and is the standard tamponade for small/medium holes; the flight ban is 3 weeks. C3F8 (14 per cent perfluoropropane) lasts 6–8 weeks and is reserved for large, chronic, re-do or myopic holes where prolonged tamponade aids closure; the flight ban is 6–8 weeks. Your surgeon will choose based on the hole size, the duration the hole has been open, the technique used and any history of high myopia or previous failed surgery.

What happens to my vision while the gas bubble is in the eye?

While the gas bubble fills the vitreous cavity the operated eye sees only light and shadow because the bubble blocks light from reaching the retina. As the bubble absorbs, you will start to see the upper edge of a "horizon line" within the eye, which gradually descends as the bubble shrinks; vision returns from the top of the visual field downwards over 2–4 weeks (SF6) or 6–8 weeks (C3F8). Vision in the fellow eye is unaffected throughout. Do not be alarmed by the loss of vision in the operated eye — it is expected and entirely reversible.

Will I need cataract surgery afterwards?

Yes, in almost all phakic patients over 55. Vitrectomy reliably accelerates cataract formation (nuclear sclerosis) so that a visually significant cataract appears within 6–12 months of surgery. For this reason most surgeons recommend a combined phacovitrectomy (cataract surgery + IOL + vitrectomy + ILM peel + gas) in the same operation in phakic eyes — it costs more up front (£8,500–£11,500) but avoids a second operation, second anaesthetic, second recovery and second period of disability. Pseudophakic eyes (those that have already had cataract surgery) do not need this and have macular hole vitrectomy alone.

When can I fly after macular hole surgery?

Absolutely no air travel until the gas bubble has fully absorbed. For 20 per cent SF6 that is approximately 3 weeks; for 14 per cent C3F8 it is 6–8 weeks. The cabin pressure drop at altitude causes the residual gas to expand catastrophically, raising the intraocular pressure to levels that cause irreversible optic nerve damage. Your surgeon will give you a wrist band and a signed letter to confirm flight clearance once your post-op OCT shows the bubble has gone.

When can I drive after macular hole vitrectomy?

Most patients can drive at 3–6 weeks (SF6) or 6–8 weeks (C3F8) once the gas bubble has absorbed below the visual axis and the operated eye meets the DVLA visual standard: Snellen 6/12 with both eyes open and a 120-degree horizontal field of vision. Your consultant will sign off driving at the 4-week or 6-week review.

Can a macular hole come back after closure?

Late re-opening is uncommon (2–5 per cent over 5 years), and more likely in eyes with persistent cystoid macular oedema, an under-treated epiretinal membrane or in high myopia. Re-do surgery is offered and typically uses an ILM flap or autologous ILM transplant technique because the original ILM has already been peeled. Annual macular OCT surveillance from year 2 is recommended.

Standard PPV vs ILM flap vs autologous transplant - which is right for me?

Standard PPV with ILM peel is the workhorse for primary stage 2–3 macular holes with MLD up to ~400 microns. Inverted ILM flap (Michalewska 2010) is for large stage 4 holes > 400 microns or chronic holes, with closure 90–98 per cent and better visual outcome. Free ILM flap or autologous ILM transplant is reserved for re-do operations where the ILM has already been peeled. The decision is made by a UK GMC-registered consultant ophthalmologist with vitreoretinal subspecialty interest after macular OCT and full work-up. See the macular hole surgery outcomes overview for the comparison in detail.

Methodology and sources

This UK 2026 patient pricing and pathway guide was prepared by the Eye Surgery Clinic editorial team and reviewed by a UK GMC-registered consultant ophthalmologist with vitreoretinal subspecialty interest. Pricing reflects a CQC-registered UK vitreoretinal sample audited against published 2024 to 2026 self-pay tariffs from the major London vitreoretinal providers. Clinical statements are anchored on:

• Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes. Arch Ophthalmol 1991; 109: 654-659
• Brooks HL Jr. Macular hole surgery with and without internal limiting membrane peeling. Ophthalmology 2000; 107: 1939-1948
• Michalewska Z, et al. Inverted internal limiting membrane flap technique for large macular holes. Ophthalmology 2010; 117: 2018-2025
• Duker JS, et al. The International Vitreomacular Traction Study Group classification (IVTS). Ophthalmology 2013
• Lois N, et al. Internal limiting membrane peeling versus no peeling for idiopathic full-thickness macular hole (FILMS). Ophthalmology 2011
• Manchester Large Macular Hole Study (Steel et al.) on inverted ILM flap outcomes
• Stalmans P, et al. Enzymatic vitreolysis with ocriplasmin (MIVI-TRUST). N Engl J Med 2012; NICE TA297
• British Eye and Vitreoretinal Surgery (BEAVRS) UK national vitreoretinal audit
• Royal College of Ophthalmologists Vitreoretinal Subspecialty Commissioning Guidance
• American Academy of Ophthalmology Retina Preferred Practice Pattern (idiopathic macular hole)
• Cochrane Database of Systematic Reviews on macular hole surgery and posturing
• Care Quality Commission (CQC) inspection reports for major UK vitreoretinal units
• General Medical Council (GMC) Good Medical Practice and consent guidance

This page is editorial and educational. It is not personalised medical advice. Macular hole suitability and the specific surgical technique can only be confirmed by an in-person vitreoretinal consultation with a UK GMC-registered consultant ophthalmologist with vitreoretinal subspecialty interest, including dilated fundoscopy, high-resolution macular OCT and the IVTS classification of the hole.

Book your London macular hole consultation

Speak directly to a UK GMC-registered consultant ophthalmologist with vitreoretinal subspecialty interest. Same-week consultation slots are usually available. Slit-lamp, dilated indirect fundoscopy, high-resolution macular OCT (Spectralis or Cirrus), ultra-widefield fundus imaging, axial length biometry and a defensible IVTS-staged surgical plan are included. Confidential, no-obligation review of whether standard PPV + ILM peel, inverted ILM flap or autologous transplant is right for your hole.

Related reading: Private vitrectomy surgery cost UK · Private epiretinal membrane peel surgery London · Private retinal detachment surgery London · Macular hole surgery outcomes overview